JAYPIRCA

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, France, Ireland, Italy, Lithuania, Romania.

Active ingredients

The drug JAYPIRCA contains one active pharmaceutical ingredient (API):

1	Pirtobrutinib UNII JNA39I7ZVB - PIRTOBRUTINIB
	Pirtobrutinib is a reversible, noncovalent inhibitor of BTK. BTK is a signalling protein of the B-cell antigen receptor (BCR) and cytokine receptor pathways. In B-cells, BTK signalling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. Pirtobrutinib binds to wild type BTK as well as BTK harboring C481 mutations leading to inhibition of BTK kinase activity.
	Read more about Pirtobrutinib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
JAYPIRCA Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01EL05		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EL Bruton's tyrosine kinase (BTK) inhibitors
Discover more medicines within L01EL05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3059142, 3059153, 3059164, 3059175, 3059186, 3059197, 3059209, 3059210, 3059221
FR	Base de données publique des médicaments	67881720, 68606652
IT	Agenzia del Farmaco	050942010, 050942022, 050942034, 050942046, 050942059, 050942061, 050942073, 050942085, 050942097
LT	Valstybinė vaistų kontrolės tarnyba	1098037, 1098038, 1098039, 1098040, 1098041, 1098042, 1098043, 1098044, 1098045
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W69920001, W69921001
US	FDA, National Drug Code	0002-6902, 0002-7026